Is a complete AKBA research report available?

No complete published report is available for Akebia Therapeutics, Inc. (AKBA) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Akebia Therapeutics, Inc. (AKBA)

NASDAQ: AKBA · USD

$1.35

+0.09 (+7.1%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first AKBA analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	362.1M
Revenue (ttm)	232.4M
Net income (ttm)	-20.5M
EPS (ttm)	-$0.08
Shares out	268.3M
Volume	3,116,980
Beta	0.24
Price target	$4.20	+211.1%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 232.4M
Net income (ttm): -20.5M
EPS (ttm): -$0.08
Market cap: 362.1M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All AKBA indicators

Market & fundamental data

Available fields

232

Groups with data

Currency

USD

Showing 232 of 232 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001517022
Company name	Akebia Therapeutics, Inc.
Country	United States
Country code	US
Cusip	00972D105
Employees	194
Employees Change	13%
Employees Change Percent	7.18
Enterprise value	$397M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
Industry PE	115.3
Industry PE Fwd	13.99
IPO Date	2014-03-20
Isin	US00972D1054
Last refreshed	2026-07-31
Market cap	$362.1M
Market cap category	Small-Cap
Price	$1.35
Price currency	USD
Rev Per Employee	1,197,958.76x
Sector	Healthcare
Sector PE	45.56
Sector PE Fwd	24.38
Sic	2834
Symbol	AKBA
Website	https://www.akebia.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-5.66%
EV Sales Forward	2.09x
EV/EBIT	75.07x
EV/EBITDA	60.41x
EV/FCF	6.61x
EV/Sales	1.71x
FCF yield	16.58%
P/B ratio	13.21x
P/S ratio	1.56x
PS Forward	1.91x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	2.28%
EBITDA Margin	2.83%
FCF margin	25.83%
Gross margin	81.94%
Gross Profit	$190.4M
Gross Profit Growth	24.21%
Gross Profit Growth Q	-11%
Gross Profit Growth3 Y	-9.95%
Gross Profit Growth5 Y	-0.83%
Net Income	$-20.5M
Net Income Growth Years	1%
Pretax Margin	-8.07%
Profit Margin	-8.83%
Profit Per Employee	$-105,727
ROA	2.02
Roa5y	-9.1
ROCE	2.8
ROE	-78.96
ROIC	3.05

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-17.24%
Cagr1y	-61.56%
Cagr3y	-5.11%
Cagr5y	-11.74%
EPS Growth Years	1
Revenue Growth	25.69x
Revenue Growth Q	-6.61x
Revenue Growth Years	1x
Revenue Growth3 Y	-4.98x
Revenue Growth5 Y	-2.15x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.69
Assets	$362.5M
Cash	$162.6M
Current Assets	$243.5M
Current Liabilities	$173.9M
Debt	$197.5M
Debt EBITDA	$30.06
Debt Equity	$7.22
Debt FCF	$3.29
Equity	$27.4M
Interest Coverage	0.25
Liabilities	$335.1M
Long Term Assets	$119M
Long Term Liabilities	$161.3M
Net Cash	$-34.9M
Net Cash By Market Cap	$-9.63
Net Debt EBITDA	$5.31
Net Debt Equity	$1.27
Net Debt FCF	$0.58
Tangible Book Value	$-31.7M
Tangible Book Value Per Share	$-0.12
WACC	6.57

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.4
Inventory Turnover	2.56
Net Working Capital	$-53.6M
Quick ratio	1.3
Working Capital	$69.6M
Working Capital Turnover	$2.55

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-21.26%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-84.92%
1Y total return	-61.54%
200-day SMA	1.48
3Y total return	-14.56%
50-day SMA	1.14
50-day SMA vs 200-day SMA	50under200
5Y total return	-46.43%
All Time High	31
All Time High Change	-95.65%
All Time High Date	2014-06-20
All Time Low	0.24
All Time Low Change	460.17%
All Time Low Date	2022-10-24
ATR	0.08
Beta	0.24
Beta1y	0.53
Beta2y	1.14
Ch YTD	-16.15
High	1.36
High52	3.81
High52 Date	2025-07-30
High52ch	-64.57%
Low	1.24
Low52	0.82
Low52 Date	2026-06-10
Low52ch	64.09%
Ma50ch	18.73%
Premarket Change Percent	-0.13
Premarket Price	$1.26
Premarket Volume	740
Price vs 200-day SMA	-9.03%
RSI	59.85
RSI Monthly	44.19
RSI Weekly	48.91
Sharpe ratio	-0.9x
Sortino ratio	-1.04
Total Return	-21.26%
Tr YTD	-16.15
Tr1m	21.62%
Tr1w	10.66%
Tr3m	-0.74%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	5
Analyst Count Top	3
Analyst Price Target Top	$4.67
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.03
Earnings Revenue Estimate	49,518,960x
Earnings Revenue Estimate Growth	-20.73x
Operating Income	$10.8M
Operating margin	4.67
Price target	$4.2
Price Target Change	$211
Price Target Change Top	$246

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	262,014,425%
Float Percent	97.67%
Net Borrowing	-4,350,000
Shares Insiders	2.33%
Shares Institutions	41.11%
Shares Out	268,258,243
Shares Qo Q	0.63%
Shares Yo Y	21.26%
Short Float	7.28%
Short Ratio	3.26
Short Shares	7.11

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$47.3M
Adjusted OCF	47,608,000
Average Volume	3,192,100.25x
Bv Per Share	0.1
CAPEX	$-335,000
Ch10y	-84.92
Ch1m	21.62
Ch1w	10.66
Ch1y	-61.54
Ch3m	-0.74
Ch3y	-14.56
Ch5y	-46.43
Ch6m	-6.9
Change	7.14%
Change From Open	8.87
Close	1.26
Days Gap	-1.59
Depreciation Amortization	1,283,000
Dollar Volume	4,207,923
Earnings Date	2026-08-05
Earnings Time	amc
EBIT	$5.3M
EBITDA	$6.6M
EPS	$-0.08
F Score	5
FCF	$60M
FCF EV Yield	15.12x
FCF Per Share	$0.22
Financing CF	-2,941,000
Fiscal Year End	December
Founded	2,007
Goodwill	59,044,000
Income Tax	$1.8M
Investing CF	-8,142,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Ma150	1.3
Ma150ch	3.77%
Ma20	1.32
Ma20ch	1.96%
Net CF	49,289,000
Next Earnings Date	2026-08-05
Open	1.24
Optionable	Yes
P FCF Ratio	6.03
P FCF Ratio SBC	7.66
P OCF Ratio	6
P OCF Ratio SBC	7.61
Position In Range	91.67
Post Close	1.35
Postmarket Change Percent	0.73
Postmarket Price	$1.36
Ppne	3,421,000
Pre Close	1.26
Price Date	2026-07-30
Price EBITDA	$55.1
Relative Volume	0.98x
Revenue	232,404,000x
SBC By Revenue	5.49x
Share Based Comp	12,764,000
Tax By Revenue	0.75x
Tr6m	-6.9%
Us State	Massachusetts
Volume	3,116,980
Z Score	-4.43

Akebia Therapeutics, Inc. (AKBA)

Coverage state: Market snapshot only — no published research

Generate the first AKBA analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · AKBA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All AKBA indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on AKBA

Frequently asked questions